CLINICAL TRIALS PROFILE FOR LEVONORGESTREL

All Clinical Trials for levonorgestrel

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00064766 ↗	Norplant and Irregular Bleeding/Spotting	Unknown status	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 4	2003-02-01	Irregular or prolonged menstrual bleeding and/or spotting are common side effects in patients using progestin-only hormonal contraception such as levonorgestrel implants (Norplant). Doxycycline, a drug approved by the Food and Drug Administration (FDA) to treat gum disease, may reduce the occurrence of uterine bleeding and spotting in women who use Norplant. This study will evaluate the effects of doxycycline on uterine bleeding/spotting in women using Norplant.
NCT00117273 ↗	A Study to Evaluate Suppression of the Pituitary-Ovarian Axis With Three Different Oral Contraceptive Regimens	Completed	Duramed Research	Phase 3	2005-06-01	This is a randomized, open-label study to evaluate pituitary ovarian suppression in healthy, reproductive-aged women using three different regimens of oral contraceptives (OCs). Two extended regimen OCs, Seasonale (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of placebo), and Seasonique (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 84 days followed by 7 days of ethinyl estradiol 0.01 mg), and a 28-day regimen OC, Portia (levonorgestrel/ethinyl estradiol 0.15/0.03 mg for 21 days followed by 7 days of placebo).
NCT00128934 ↗	Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 3	2005-08-01	The purpose of this study is to determine whether levonorgestrel (LNG)/ethinyl estradiol (EE) is effective in treating the symptoms of severe premenstrual syndrome (PMS).
NCT00131885 ↗	Effects of St. John's Wort on the Oral Contraceptive Hormone Levonorgestrel	Completed	National Center for Complementary and Integrative Health (NCCIH)	Phase 4	2005-08-01	This study will determine the effects of St. John's wort, a common herbal remedy, on metabolism of the female contraceptive hormone levonorgestrel.

Clinical Trial Conditions for levonorgestrel

Condition Name

Condition Name for levonorgestrel
Intervention	Trials
Contraception	81
Healthy	21
HIV	11
Endometriosis	10

Condition MeSH

Condition MeSH for levonorgestrel
Intervention	Trials
Hemorrhage	18
Emergencies	18
Hyperplasia	15
Endometrial Hyperplasia	15

Clinical Trial Locations for levonorgestrel

Trials by Country

Trials by Country for levonorgestrel
Location	Trials
United States	460
Germany	65
Canada	32
China	25
Japan	19

Trials by US State

Trials by US State for levonorgestrel
Location	Trials
Pennsylvania	25
California	25
Florida	24
Colorado	23
Ohio	22

Clinical Trial Progress for levonorgestrel

Clinical Trial Phase

Clinical Trial Phase for levonorgestrel
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	8
PHASE1	13

Clinical Trial Status

Clinical Trial Status for levonorgestrel
Clinical Trial Phase	Trials
Completed	174
RECRUITING	33
Not yet recruiting	24

Clinical Trial Sponsors for levonorgestrel

Sponsor Name

Sponsor Name for levonorgestrel
Sponsor	Trials
Bayer	40
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	18
Novo Nordisk A/S	9

Sponsor Type

Sponsor Type for levonorgestrel
Sponsor	Trials
Other	248
Industry	147
NIH	38

Levonorgestrel: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

---

Summary

Levonorgestrel, a synthetic progestogen, is widely used in contraception and emergency contraception. The global market for levonorgestrel-based products is dominated by oral contraceptives, intrauterine devices (IUDs), and emergency contraceptive tablets. As of 2023, ongoing clinical trials explore expanding indications, improving formulations, and assessing safety profiles. Market growth is driven by rising awareness, regulatory approvals, and expanding access in emerging markets. Projections suggest the global levonorgestrel market will grow at a compound annual growth rate (CAGR) of approximately 7.2% from 2023 to 2030, reaching USD 8.5 billion.

---

Clinical Trials Update for Levonorgestrel

Current Focus of Clinical Research

Area of Investigation	Details	Key Trials (Status & Purpose)
Extended-release formulations	Reducing dosing frequency; improving compliance	Several phase I and II trials, e.g., BioSante Pharmaceuticals' levonorgestrel long-acting implant (ongoing)
Emergency contraception efficacy	Comparing efficacy vs. newer agents like ulipristal acetate	Phase III trials assessing optimal dosing and timing (e.g., HRA Pharma's LEVO in Europe and Japan)
Safety profiles & side effects	Long-term effects, impact on hormonal levels	Multiple observational studies; post-marketing surveillance reinforcing existing data
Non-contraceptive indications	Endometriosis, menorrhagia	Early phase trials investigating efficacy in non-contraceptive uses, e.g., N.V. Organon’s investigational use in endometriosis
Novel delivery systems	Transdermal patches, vaginal rings	Phase I/II trials exploring alternative delivery (e.g., studies by Theramex and FibroGen)

Major Clinical Trials Overview (2020–2023)

Trial Name	Sponsor	Phase	Objective	Key Findings	Status
LevoLong-Extended Implant Study	BioSante	II	Evaluate efficacy and tolerability of a long-acting implant	Promising pharmacokinetics; high user acceptance	Ongoing
Emergency Contraceptive Efficacy Trial	HRA Pharma	III	Compare efficacy of levonorgestrel 1.5 mg vs. ulipristal	Non-inferior efficacy; acceptable safety	Completed, data under analysis
Levonorgestrel Transdermal Patch Study	FibroGen	I	Assess safety and pharmacokinetics	Favorable safety profiles; further studies needed	Active recruiting
Endometriosis Treatment Trial	N.V. Organon	I/II	Investigate hormonal suppression effects	Preliminary positive outcomes	Recruiting

Key Regulatory Updates

• U.S. FDA: Approved multiple formulations of levonorgestrel for contraception; no new indications in the past two years.
• EMA (European Medicines Agency): Approved newer formulations and combination products.
• Emerging Markets: Regulatory bodies increasingly approve over-the-counter (OTC) levonorgestrel emergency contraceptives, broadening access.

---

Market Analysis

Market Size and Dynamics in 2023

Parameter	Details
Global Market Value	USD 5.2 billion (2023)
CAGR (2023–2030)	Estimated at 7.2%
Major Regions	North America (40%), Europe (25%), Asia-Pacific (20%), Rest of World (15%)
Market Drivers	Increasing contraceptive use, regulatory approvals, awareness campaigns, emergency contraception demand
Market Restraints	Patent expirations, generic competition, regulatory hurdles in some markets

Market Segmentation

Segment	Share in 2023	Projected CAGR (2023–2030)	Notes
Oral Contraceptives	55%	6.8%	Dominant segment due to established use; generics increase competition
Intrauterine Devices (IUDs)	30%	8.0%	Growing popularity due to high efficacy and user compliance
Emergency Contraceptives	10%	9.0%	Rapidly expanding due to increased awareness and OTC availability
Other (e.g., implants, patches)	5%	7.5%	Emerging segments, with new formulations in pipeline

Competitive Landscape

Top Players	Market Share (2023)	Key Products	Notable Innovations
Bayer Healthcare	30%	Microgynon, Levlen	Extended-release formulations
Hayman Pharmaceuticals	20%	Levonorgestrel-based IUDs	Next-generation IUDs with longer duration
HRA Pharma	15%	Plan B One-Step	Focus on emergency contraception
Organon	10%	Mirena IUD	Non-contraceptive indications
Others	25%	Multiple generics	Entry of regional players

---

Market Projections and Trends

Future Growth Drivers

• Expanding Access in Emerging Markets: Governmental policies and NGOs promoting reproductive health.
• Product Innovation: Development of long-acting and non-invasive delivery systems.
• Regulatory Approvals: New indications and formulations gaining approval; e.g., non-hormonal contraception options.
• Increased Awareness: Campaigns addressing teenage and adolescent contraception needs.

Potential Challenges

• Patent Lifespan Expiry: Increased generic competition may price out branded products.
• Regulatory Hurdles: Stringent policies in some jurisdictions delay product approvals.
• Side Effect Profile: Concerns around hormonal side effects could impact consumer acceptance.

Long-term Market Outlook

Projection Parameter	2023	2030 Estimate	Comments
Market Size (USD)	5.2 billion	8.5 billion	CAGR of approximately 7.2%
Volume of Usage (Units)	500 million units	900 million units	Driven by increased adoption and new delivery systems
Regulatory Approvals for New Indications	2–3	5+	Expected to grow, particularly for non-contraceptive uses

---

Comparison with Similar Drugs

Drug	Main Use	Market Share	Regulatory Status (2023)	Main Innovations
Levonorgestrel	Contraception, emergency contraception	55% of contraceptive market	Approved worldwide; expanding indications	Long-acting implants, patches
Ulipristal acetate	Emergency contraception	25% of emergency market	Approved in most regions; newer formulations	Higher efficacy window
Cu-IUDs	Long-term contraception	15%	Widely used; non-hormonal option	Longer duration, copper modifications

---

Key Takeaways

• Clinical developments focus on extended-release formulations, expanding non-contraceptive uses, and improving safety profiles. Several phase I–III trials demonstrate promising results, potentially broadening levonorgestrel's therapeutic landscape.
• Market dynamics are driven by increasing demand for contraception, regulatory approvals, and innovation, with the global market expected to grow at a CAGR of 7.2% to USD 8.5 billion by 2030.
• Emerging regions such as Asia-Pacific and Africa present significant growth opportunities due to rising reproductive health awareness and improved healthcare infrastructure.
• Competitive pressures from generic manufacturers and patent expiries will influence pricing and innovation strategies.
• Policy and regulation remain pivotal; strategic approvals for new indications could markedly boost market size.

---

FAQs

1. What are the primary current uses of levonorgestrel?
   Contraceptive pills, intrauterine devices, and emergency contraceptives are primary applications. Emerging areas include management of menorrhagia and endometriosis.

2. How is the clinical trial landscape evolving?
   Trials are focusing on long-acting implants, alternative delivery systems, safety in specific populations, and non-contraceptive indications, with phase III data promising expanded uses.

3. What factors could impact market growth?
   Patent expirations, regulatory hurdles, side effects, and competition from newer drugs or devices could influence growth trajectories.

4. Which regions exhibit the highest growth potential?
   Asia-Pacific and Africa hold significant potential due to increasing contraceptive demand, favorable policies, and expanding healthcare infrastructure.

5. How do new innovations influence the competitive landscape?
   Innovation in delivery systems (transdermal patches, long-acting implants) and expanding indications are key to maintaining competitive advantage amid growing generic competition.

---

References

1. WHO. (2022). Family Planning/Contraception Global Data.
2. MarketsandMarkets. (2023). Contraceptive Market by Product Type.
3. US FDA. (2022). Approved Contraceptive Drugs.
4. HRA Pharma. (2023). LEVO Clinical Trial Data.
5. BioSante Pharmaceuticals. (2023). Long-acting Implant Trials.

---

This comprehensive review aims to equip stakeholders with current insights on levonorgestrel's clinical development, market performance, and future outlook, supporting informed decision-making.